The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors
Authors: Michal R. Pijak, Igor Huzicka, Frantisek Gazdik
Journal: Annals of Internal Medicine (2005)

Letters18 October 2005The Risk for Myocardial Infarction with Cyclooxygenase-2 InhibitorsMichal R. Pijak, MD, Igor Huzicka, MD, and Frantisek Gazdik, MD, PhDMichal R. Pijak, MDFrom University Hospital, 833 01 Bratislava, Slovakia.Search for more papers by this author, Igor Huzicka, MDFrom University Hospital, 833 01 Bratislava, Slovakia.Search for more papers by this author, and Frantisek Gazdik, MD, PhDFrom University Hospital, 833 01 Bratislava, Slovakia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-8-200510180-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The population-based cohort study by Lévesque and colleagues (1) has shown that aspirin eliminated the excess risk for myocardial infarction in persons receiving low doses of rofecoxib. This finding further supports the hypothesis that aspirin might mitigate the cardiovascular risk associated with the use of selective COX-2 inhibitors (2). The authors, however, fail to explain why this risk-modifying effect of aspirin was not seen with higher doses of rofecoxib and why no increase in risk was observed with celecoxib. Experimental and clinical data suggest that a competitive interaction between these drugs and aspirin on both cyclooxygenase-1 (COX-1) ...References1. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-9. [PMID: 15809459] LinkGoogle Scholar2. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-17. [PMID: 11752357] CrossrefMedlineGoogle Scholar3. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A. 2001;98:14583-8. [PMID: 11717412] CrossrefMedlineGoogle Scholar4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9. [PMID: 9077376] CrossrefMedlineGoogle Scholar5. Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G, et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol. 2003;139:1351-9. [PMID: 12890715] CrossrefMedlineGoogle Scholar6. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A. 2004;101:15178-83. [PMID: 15471991] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Michal R. Pijak, MD; Igor Huzicka, MD; Frantisek Gazdik, MD, PhDAffiliations: From University Hospital, 833 01 Bratislava, Slovakia.Disclosures: Consultancies: M.R. Pijak (Pfizer, Inc., Merck Sharpe & Dohme, Fournier Slovakia); Honoraria: M.R. Pijak (Pfizer, Inc., Merck Sharpe & Dohme, Fournier Slovakia). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Linda E. Lévesque , James M. Brophy , and Bin Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors Ken Shinmura and Roberto Bolli The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors James M. Brophy , Linda E. Lévesque , and Bin Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors Jeong A. Kim , Youn Seon Choi , Dokyung Yoon , and Kyung Hwan Cho Metrics Cited byCurrent awareness: Pharmacoepidemiology and drug safety 18 October 2005Volume 143, Issue 8 Page: 616-617 Keywords Conflicts of interest Drug interactions Drugs Enzymes Myocardial infarction Observational studies Platelets ePublished: 18 October 2005 Issue Published: 18 October 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...